Jessica Altman took over in March as executive director of California’s health insurance marketplace, which serves 1.8 million people. She warns that if Congress does not renew the tax credit enhancements that have made health plans more affordable, consumers will face significantly higher premiums, which could cause many to forgo coverage.
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
Congress is back in session, but covid diagnoses for Vice President Kamala Harris and two Democratic senators have temporarily left the Senate without a working majority to approve continued covid funding. Meanwhile, opponents of the Affordable Care Act have filed yet another lawsuit challenging a portion of the law, and we say goodbye to the late Sen. Orrin Hatch of Utah, who left a long legacy of health laws. Rachel Cohrs of STAT News, Anna Edney of Bloomberg News, and Rebecca Adams of KHN join KHN’s Julie Rovner to discuss these issues and more.
Federal funding that paid for covid testing, treatment, and vaccines for uninsured people has run out. While some states struggle to make up the difference, California is relying on other state and local programs to continue free testing.
A controversial proposal to grant HMO giant Kaiser Permanente a no-bid statewide Medicaid contract is headed for its first legislative hearing amid vocal opposition from a coalition of counties, competing health plans, community clinics, and a national health care labor union.
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
As states prepare for the end of the covid public health emergency, they are making plans to reevaluate each Medicaid enrollee’s eligibility. They will rely primarily on mail and email because not many states can text enrollees.
The company awarded the state’s Medi-Cal Rx contract was taken over by another company, Centene. That left the state with a contractor it didn’t pick — one that has been accused of overbilling nine other state Medicaid programs and is now under investigation by California.
The Biden administration unveiled a new special enrollment option aimed at signing up low-income Americans for Affordable Care Act coverage — even if it is outside of the usual annual open enrollment period. But insurers are cutting broker commissions at the same time.
